Quality Control of Medicines and Supplements Group, Pharmaceutical Quality Assurance Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Food Chem Toxicol. 2019 Jul;129:22-29. doi: 10.1016/j.fct.2019.04.032. Epub 2019 Apr 19.
Contrary to the safe usage of probiotics for years, their threat is still worthy of attention. Several risks have been explained or mentioned in the case reports, clinical trials and experimental studies. Due to a large number of probiotic products worldwide, the certainty of the safety of such products is a matter of concern. Current review appraises all the available information about a range of adverse effects by probiotics in different populations of consumers and almost all qualified investigations and reports, relevant to the adverse effects of probiotics. Furthermore, the effects of basic or original sources of probiotics were studied. The principally noticed adverse effects of probiotics are systemic infections, gastrointestinal side effects, skin complications, inflammation of endocardium, gene transfer from probiotics to the normal microbial flora, metabolic harmful impacts of probiotics, and immune system stimulation. The most at-risk groups consist of infants, elderly people, patients in hospitalized condition, and those with immunodeficiency due to a genetic or acquired disease. The existing evidence suggests careful evaluation of the risk-benefit ratio of probiotics prior to prescription or recommendation to use.
与多年来益生菌的安全使用相反,它们的威胁仍然值得关注。在病例报告、临床试验和实验研究中已经解释或提到了几种风险。由于全球有大量的益生菌产品,此类产品的安全性的确定性是一个令人关注的问题。目前的综述评估了所有关于益生菌在不同消费者群体中产生的一系列不良反应的可用信息,以及几乎所有与益生菌不良反应相关的合格调查和报告,此外还研究了益生菌的基本或原始来源的影响。益生菌主要注意到的不良反应是全身感染、胃肠道副作用、皮肤并发症、心内膜炎、益生菌向正常微生物菌群的基因转移、益生菌的代谢有害影响以及免疫系统刺激。风险最大的群体包括婴儿、老年人、住院患者以及因遗传或获得性疾病而导致免疫缺陷的患者。现有证据表明,在开处方或建议使用益生菌之前,应仔细评估其风险-效益比。